Prothrombin as Co-Factor of the Circulating Anticoagulant in Systemic Lupus Erythematosus?

1959 ◽  
Vol 03 (02) ◽  
pp. 237-256 ◽  
Author(s):  
A Loeliger ◽  
E. J. J Alsbach ◽  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
False Positive ◽  
Immune Reaction ◽  
Serum Proteins ◽  
Normal Values ◽  
Systemic Lupus ◽  
Flocculation Test ◽  
Tissue Thromboplastin ◽  
Possible Cause

SummaryA 35-year old man with lupus erythematosus of the skin is demonstrated, who also shows signs of systemic L. E.: sometimes slightly increased ESR, varying thrombocytopenia, slightly prolonged coagulation and prothrombin time, positive cepnalin-cholesterol flocculation test, biologically false positive syphilis reactions and signs of a slightly increased haemolysis. Electrophoretic examination of the serum proteins presents practically normal values, certainly no hypergammaglobulinaemia. Analytical examination of coagulation reveals hypoprothrombinaemia and an anticoagulant most probably directed against thrombocyte factor 3, intrinsic thromboplastin and tissue thromboplastin. The anticoagulant seems to be only active in the presence of prothrombin. Prothrombin therefore, is considered a co-factor of the anticoagulant. The inactive anticoagulant is localized in the gamma globulins. The possible cause of the hypoprothrombinaemia (immune reaction?) and the data in the literature are discussed.

scholarly journals Serum Proteins in Systemic Lupus Erythematosus

BMJ ◽  
1959 ◽  
Vol 2 (5155) ◽  
pp. 795-798 ◽  
Author(s):  
E. G. Rees ◽  
M. Wilkinson
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Serum Proteins ◽  
Systemic Lupus

SYSTEMIC LUPUS ERYTHEMATOSUS AND SYNDROMES POSSIBLY RELATED

PEDIATRICS ◽  
1957 ◽  
Vol 19 (6) ◽  
pp. 1109-1123
Author(s):  
M. A. Ogryzlo ◽  
H. A. Smythe
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Serum Proteins ◽  
Clinical Manifestations ◽  
Electrophoretic Pattern ◽  
Chemotherapeutic Agents ◽  
Systemic Lupus ◽  
Relationship Of ◽  
The Relationship

Attention is drawn to the difficulties that may be encountered in the positive identification and classification of many patients suspected of suffering from systemic lupus erythematosus. Much of this is due to a lack of specific criteria, either clinical or pathologic, for the diagnosis of the disease. The problem has been made more difficult by the recognition of a number of other syndromes that bear a superficial resemblance to systemic lupus erythematosus, yet differ in clinical manifestations, natural course, prognosis and other respects. A feature common to the group is the presence of the L.E. cell phenomenon. The related conditions differ from lupus enythematosus in that the L.E. phenomenon may only be demonstrable intermittently especially during severe exacerbations of the disease, while at the same time disturbances in the electrophoretic pattern of the serum proteins may be much more profound. In systemic rheumatoid disease the prognosis without steroid therapy is better than in systemic lupus erythematosus, although the morbidity may be great. The reactions which follow administration of certain chemotherapeutic agents are of considerable interest, particularly in view of the similarity to lupus erythematosus and rheumatoid arthritis, and the reversibility on withdrawal of the offending agent. The relationship of these syndromes to each other and to classical systemic lupus erythematosus has not yet been resolved, and inclusion of them under the diagnosis of systemic lupus erythematosus at this time must be regarded as premature.

scholarly journals A clinical study of the lupus anticoagulant

Blood ◽  
1976 ◽  
Vol 48 (4) ◽  
pp. 499-509 ◽  
Author(s):  
MA Schleider ◽  
RL Nachman ◽  
EA Jaffe ◽  
M Coleman
Keyword(s):  
Systemic Lupus Erythematosus ◽  
New York ◽  
Clinical Study ◽  
Lupus Erythematosus ◽  
Lupus Anticoagulant ◽  
Coagulation Test ◽  
Systemic Lupus ◽  
York Hospital ◽  
Tissue Thromboplastin ◽  
Activator Complex

Abstract Eighty-three patients with circulating anticoagulants were studied at The New York Hospital. The lupus-type anticoagulant, an inhibitor of the prothrombin activator complex, was demonstrated in 58 patients. The inhibitor was identified using the blood and tissue thromboplastin inhibition tests. Inhibition by the lupus anticoagulant was augmented in 67% of these patients by a cofactor present in normal plasma. The lupus inhibitor was detected primarily because of an unsuspected abnormal coagulation test. One-half of the patients with the lupus-type anticoagulant did not have systemic lupus erythematosus.

scholarly journals A clinical study of the lupus anticoagulant

Blood ◽  
1976 ◽  
Vol 48 (4) ◽  
pp. 499-509
Author(s):  
MA Schleider ◽  
RL Nachman ◽  
EA Jaffe ◽  
M Coleman
Keyword(s):  
Systemic Lupus Erythematosus ◽  
New York ◽  
Clinical Study ◽  
Lupus Erythematosus ◽  
Lupus Anticoagulant ◽  
Coagulation Test ◽  
Systemic Lupus ◽  
York Hospital ◽  
Tissue Thromboplastin ◽  
Activator Complex

Eighty-three patients with circulating anticoagulants were studied at The New York Hospital. The lupus-type anticoagulant, an inhibitor of the prothrombin activator complex, was demonstrated in 58 patients. The inhibitor was identified using the blood and tissue thromboplastin inhibition tests. Inhibition by the lupus anticoagulant was augmented in 67% of these patients by a cofactor present in normal plasma. The lupus inhibitor was detected primarily because of an unsuspected abnormal coagulation test. One-half of the patients with the lupus-type anticoagulant did not have systemic lupus erythematosus.

scholarly journals Correlation of Lipid Peroxidation and Glutathione Levels with severity of Systemic Lupus Erythematosus: a Pilot study from Single Center

2008 ◽  
Vol 11 (3) ◽  
pp. 30 ◽  
Author(s):  
Karunrat Tewthanom
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Oxidative Status ◽  
Glutathione Level ◽  
Limited Data ◽  
Systemic Lupus ◽  
Plasma Glutathione ◽  
Chronic Autoimmune Disease ◽  
Possible Cause ◽  
Plasma Malondialdehyde

Abstract Systemic Lupus Erythematosus (SLE) is a multifactoral chronic autoimmune disease with unidentified etiology. Imbalance of oxidative status is one possible cause of active disease. Plasma malondialdehyde (MDA) and plasma glutathione (GSH) level have been used as a determinate of oxidative status. Limited data has examined these 2 parameters by severity of SLE. Therefore, the purpose of this study was to determine if an association between plasma MDA and plasma GSH level with the severity of SLE . Twenty healthy volunteers (3 Men, 17 women) and 44 SLE patients (2 Men and 42 Women) participated in this study. SLE participants were classified by the severity of disease (mild, moderate or severe). The plasma MDA and plasma Glutathione level were measured. The correlation of plasma MDA and plasma Glutathione levels with the severity of SLE disease were determined. No correlation of plasma MDA level among the 4 groups with different severity of SLE (Control, mild, moderate, and severe of SLE patients) was observed at p

Sign in / Sign up

Export Citation Format

Share Document